Suchergebnisse

"Pharmaceutical Public Policy provides the understanding and framework required for effective organization, financing, and delivery of pharmaceutical products and services. It supplies an overview of the policy process as well as the roles of legislation and regulation in pharmaceutical policy. The book identifies the goals, objectives, and key policy issues of concern to stakeholders involved in the development of products, use of pharmaceuticals in healthcare, and administration of insurance programs by both the private and government sectors. Policy issues examined include the appropriateness of prescribing and patient adherence. Addressing questions of access, quality, and cost, the book considers the operation of the Affordable Care Act and Medicare Part D. It details the responsibilities of Federal providers of pharmaceutical care and private and public payers such as managed care organizations, pharmacy benefit managers, Medicare, and Medicaid. The book covers the policies and practices involved in promoting pharmaceutical products. It also considers pharmacoeconomics as a response to market failure. Finally, the book describes the market, the role of the manufacturer, drug shortages, and the responsibilities of the FDA."--

In this study we assess the implementation and impact of reference-based pricing (RBP) in British Columbia (BC), Canada, and other OECD (Organization for Economic Cooperation and Development) jurisdictions within an evaluative framework. This was accomplished by conducting a review of prior studies and an analysis of secondary utilization and cost data. Our review of previous work found the introduction of RBP in other OECD jurisdictions was followed by a temporary reduction in pharmaceutical expenditure growth but the rate of growth soon returned to those of previous years. Early results from the BC experience show similar declines in expenditures within reference drug categories, but it remains to be seen if this will continue in the long term. Although early results suggest RBP in BC may be achieving its goals, more work is needed before it can be declared a success. A more balanced evaluation will need to address nonmonetary issues such as impact on the quality of patient care or extent of cost shifting to other areas of the health system. The policy questions raised in this study indicate decision makers should be cautious when thinking of any wider application of referencebased pricing.